Quick Recap
Hematology System, Protocol 4/8. This protocol focuses on the neutropenic-fever-specific algorithm and risk stratification; broader immunocompromised-host infection epidemiology (SOT/HSCT timelines, CD4-stratified HIV differential) is covered in the Opportunistic Infections protocol (Infectious Diseases System) and cross-referenced rather than duplicated here.
1. Definitions
Severe neutropenia: ANC <500 cells/mm3, OR anticipated decline to <500 within 48 hours. Prolonged (>7 days) and severe neutropenia both independently increase bloodstream and other serious infection risk.
Neutropenic fever: a single temperature >=38.3C (101F), OR a persistent temperature >=38.0C (100.4F) for more than 1 hour, in a severely neutropenic patient.
A medical EMERGENCY — more than half of all neutropenic fever patients are ultimately found to have an established or occult infection. Severe neutropenia mutes the host inflammatory response, so fever is frequently the FIRST AND ONLY sign of infection — do not wait for other localizing signs before treating aggressively.
2. Risk Stratification
While formal validated risk-scoring tools exist (e.g., MASCC score, incorporating burden of illness, hypotension, COPD, solid tumor/no prior fungal infection, no dehydration, outpatient status, and age) to identify LOW-risk patients potentially suitable for oral antibiotics/outpatient management, the ICU-relevant population by definition typically falls into the HIGH-risk category (hemodynamic instability, significant comorbidity, or already hospitalized) — this protocol focuses on that high-risk, inpatient/ICU management pathway rather than the outpatient oral-antibiotic algorithm.
3. Neutropenia-Specific Infectious Considerations (Beyond Standard ICU Infections)
Common ICU infections (pneumonia, UTI, bloodstream infection) remain the most frequent causes, PLUS:
- Chemotherapy-induced mucositis raises sinus/oropharyngeal/GI infection risk — invasive fungal sinusitis is the most feared given its high morbidity/mortality
- Neutropenic enterocolitis (typhlitis): necrotizing cecal infection extending to terminal ileum/ascending colon, risking perforation, peritonitis, hemorrhage, sepsis
- GI mucosal translocation can precipitate bloodstream infection with Enterococcus, Candida, Enterobacteriaceae, other gram-negatives
- Viral reactivation (HSV, CMV, EBV, VZV, HHV-6) with varied presentations; prior TB history warrants reactivation consideration
- Prolonged/severe neutropenia specifically raises invasive FUNGAL infection risk (Candida, Aspergillus, Fusarium, Cryptococcus, dimorphic mycoses) and Nocardia
4. Immediate Stabilization (ABCDE)
Circulation: treat as evolving septic shock if hemodynamically unstable — apply full Septic Shock protocol principles (Infectious Diseases System).
Management Algorithm:
- Blood cultures obtained, then EARLY empiric broad-spectrum antimicrobial therapy started AS SOON AS FEVER IS RECOGNIZED — early empiric therapy decreases mortality and takes precedence once cultures are drawn
- Initial monotherapy with an antipseudomonal cephalosporin, beta-lactam, or carbapenem (broad gram-negative coverage) +/- vancomycin for gram-positive coverage, guided by local resistance patterns — despite the epidemiologic shift toward gram-positive organisms in recent decades, broad-spectrum empiric coverage remains recommended pending workup completion
- If blood cultures remain negative and fever persists >5 days: empiric ANTIFUNGAL therapy is usually warranted to cover mold infections
- Empiric ANTIVIRAL therapy is generally NOT recommended unless characteristic HSV/VZV skin lesions are identified, or active influenza/COVID-19 is confirmed in the community
- Optimal duration of therapy remains UNSETTLED, particularly when no infectious etiology is identified — an active research area; engage infectious disease rather than applying a fixed course
Checklist:
5. Investigations
Blood cultures (peripheral + any central line, before or concurrent with antibiotics), CBC with differential, CXR, urinalysis/culture, imaging with low threshold given muted symptom localization, serum galactomannan if invasive Aspergillus a concern, stool studies if GI symptoms present (screen for C. difficile given broad-spectrum antibiotic exposure history), site-specific cultures per localizing symptoms.
6. Organ Support
Standard ICU supportive care; source control (catheter removal if infected) per general principles; growth factor support (G-CSF) per hematology/oncology guidance to accelerate count recovery, though this does not replace prompt antimicrobial therapy.
7. Consultation Matrix
Consultation | Trigger | Timing |
Infectious Disease | All neutropenic fever, especially persistent fever >5 days or diagnostic uncertainty | Immediate |
Hematology/Oncology | Underlying malignancy management, G-CSF consideration | Immediate |
8. Monitoring Framework
Serial temperature and clinical status (trend matters given blunted symptom expression), ANC trend (recovery marker and fever-resolution correlate), blood culture follow-up, imaging follow-up per specific concern.
9. Complications
Progression to septic shock, invasive fungal sinusitis/dissemination, neutropenic enterocolitis with perforation, missed diagnosis from atypical/muted presentation. Prevention: immediate empiric antibiotic therapy upon fever recognition, low threshold for imaging/subspecialty involvement given symptom-masking. Rescue: antifungal escalation at the 5-day threshold, standard septic shock rescue therapies, surgical consultation for typhlitis with perforation concern.
10. Escalation & De-escalation
Escalate: persistent fever >5 days with negative cultures -> add empiric antifungal coverage; hemodynamic instability -> full septic shock management.
De-escalate: ANC recovering, cultures negative/organism-directed therapy established, clinical improvement -> narrow antimicrobial coverage per culture data and infectious disease guidance.
11. ICU Discharge Criteria
Hemodynamically stable, ANC recovering or infectious source controlled, antimicrobial regimen narrowed and on a defined course, no evidence of ongoing neutropenia-specific complication (typhlitis, invasive fungal disease).
12. Documentation & Medicolegal Checklist
13. Key Guidelines
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA. Clin Infect Dis. 2011;52(4):e56-e93.
14. Controversies
Optimal duration of antimicrobial therapy without an identified source remains genuinely unsettled and an active research area. MASCC-based low-risk identification for outpatient management is well-validated but of limited direct relevance to the already-hospitalized/ICU population this protocol addresses.
15. References
- Mazi PB, Liang SY. Infections in the Immunocompromised Host (Neutropenia section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 43).
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA. Clin Infect Dis. 2011;52(4):e56-e93.
See also: Opportunistic Infections (Infectious Diseases System) for the broader immunocompromised-host infection framework (SOT/HSCT timelines, HIV CD4-stratified differential); Sepsis/Septic Shock (Infectious Diseases System) for hemodynamic management if shock develops.